MapLight officer plans $199K stock sale

An officer of MapLight Therapeutics filed Form 144 for a planned Rule 10b5-1 sale of 16,509 shares against an outstanding base of 52.85 million shares.

Rhea-AI Filing Summary

MapLight Therapeutics, Inc. (MPLT) received a Form 144 notice from officer Kristopher Hanson covering a proposed sale of 16,509 shares of common stock through Jefferies LLC on NASDAQ under Rule 144. The shares were acquired from vested restricted stock units, and sales are pursuant to a Rule 10b5-1 selling plan adopted on December 29, 2025. The filing references 52,850,000 shares of common stock outstanding. In the prior three months, Hanson reported Rule 144 sales on July 15, 16, and 17, 2026.

Key Figures

Shares to be sold under Form 144: 16,509 shares Aggregate market value of shares to be sold: $199,428.72 Shares outstanding: 52,850,000 shares +4 more

7 metrics

Shares to be sold under Form 144 16,509 shares Proposed sale of MapLight Therapeutics common stock under Rule 144

Aggregate market value of shares to be sold $199,428.72 Market value associated with 16,509 shares in the Form 144

Shares outstanding 52,850,000 shares Referenced common stock outstanding for MapLight Therapeutics

Shares sold on July 15, 2026 7,260 shares Rule 144 sale during the past three months by Kristopher Hanson

Shares sold on July 16, 2026 8,118 shares Rule 144 sale during the past three months by Kristopher Hanson

Shares sold on July 17, 2026 1,130 shares Rule 144 sale during the past three months by Kristopher Hanson

Rule 10b5-1 plan adoption date December 29, 2025 Date the selling plan governing these sales was adopted

Key Terms

Rule 144, restricted stock units, 10b5-1 Selling plan, Form 144

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

restricted stock units financial

"The securities to be sold were acquired upon the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

10b5-1 Selling plan regulatory

"All Sales are to be made pursuant to a previously signed/adopted 10b5-1 Selling plan"

Form 144 regulatory

"144: Securities To Be Sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for MapLight Therapeutics (MPLT)?

The filing discloses that officer Kristopher Hanson plans to sell up to 16,509 shares of MapLight Therapeutics common stock under Rule 144, through Jefferies LLC on NASDAQ, with the shares coming from vested restricted stock units.

How many MapLight Therapeutics (MPLT) shares are covered and what is their value?

The notice covers 16,509 shares of MapLight Therapeutics common stock with an indicated aggregate market value of $199,428.72, based on the price information included in the Form 144 securities section.

What share count baseline is referenced for MapLight Therapeutics (MPLT)?

The Form 144 references 52,850,000 shares of MapLight Therapeutics common stock outstanding, providing a baseline share count for context relative to the 16,509 shares covered by the proposed sale notice.

What is the source of the shares Kristopher Hanson may sell in MPLT?

The filing states that the securities to be sold were acquired upon the vesting of restricted stock units during the period from July 30, 2023 through July 15, 2026, indicating they are equity compensation rather than open-market purchases.

Were there recent Rule 144 sales by Kristopher Hanson in MapLight Therapeutics (MPLT)?

Yes. The filing lists sales during the past three months: 7,260 shares on July 15, 2026, 8,118 shares on July 16, 2026, and 1,130 shares on July 17, 2026, each identified as MapLight Therapeutics common stock.

Is the planned MPLT share sale under a Rule 10b5-1 trading plan?

Yes. The remarks state that all sales are to be made pursuant to a previously signed/adopted Rule 10b5-1 selling plan dated December 29, 2025, and that representations regarding material non-public information were made as of the plan’s adoption.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/16/2026 - 04:21 PM Accepted by SEC EDGAR 09/16/2026 - 04:20 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001789970
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	MapLight Therapeutics, Inc.
SEC File Number	001-42914
Address of Issuer	800 CHESAPEAKE DRIVE REDWOOD CITY CALIFORNIA 94063
Phone	650-839-4360
Name of Person for Whose Account the Securities are To Be Sold	Hanson Kristopher
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Avenue, 4th Floor New York NY 10022	16509	199428.72	52850000	09/16/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/30/2023	Vested RSU	Maplight Therapeutics, Inc.			16509	07/30/2023	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Kris Hanson 800 Chesapeake Drive Redwood City CA 94063	Maplight Therapeutics, Inc.	07/15/2026	7260	266341.09
Kris Hanson 800 Chesapeake Drive Redwood City CA 94063	Maplight Therapeutics, Inc.	07/16/2026	8118	298606.02
Kris Hanson 800 Chesapeake Drive Redwood City CA 94063	Maplight Therapeutics, Inc.	07/17/2026	1130	42825.76

144: Remarks and Signature

Remarks	All Sales are to be made pursuant to a previously signed/adopted 10b5-1 Selling plan dated 12/29/2025, and all representations regarding material non-public information were made as of the adoption of the plan. The securities to be sold were acquired upon the vesting of restricted stock units during the period of 7/30/2023 through 7/15/2026.
Date of Notice	09/16/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/29/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	KRISTOPHER L HANSON
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)